News | Vascular Access | March 31, 2017

FDA Recalls Merit Medical Systems' Prelude Short Sheath Introducer

Class I recall initiated over reports that sheath may separate during use, which agency says may cause serious injury or death.

Merit Medical, FDA Class I recall, Prelude Short Sheath Introducer

March 31, 2017 — The U.S. Food and Drug Administration (FDA) announced it has initiated a Class I recall of the Merit Prelude Short Sheath Introducer, warning that a manufacturing defect may cause the tip to separate from the sheath during the separation procedure. The agency said that if this occurs, the tip could enter the patient’s bloodstream. This may result in prolonged procedure times, additional surgery to remove the tip from the patient, blood clots, internal tears and perforation to arteries or veins, excessive bleeding and death.

The Merit Prelude Short Sheath Introducer is used to guide the placement of catheters, grafts, and other medical devices into the veins and arteries. The device is also used during temporary hemodialysis, a treatment for kidney failure.

Lot numbers affected by the recall include H1041469, H1041473, H1036880 and H1041464; catalog numbers include K15-00070, K15-00170, PSS-7F-4-035MT and PSS-7F-4MT. The recall impacts products manufactured from Nov. 23-30, 2016, and distributed between Dec. 15, 2016 and Jan. 18, 2017. The FDA said a total of 1,265 units are impacted by the recall.

Merit Medical sent an Urgent Product Recall Notice to affected customers on Feb. 16, 2017, asking them to:

  • Ensure appropriate staff is aware of the notice;
  • Quarantine any affected products and discontinue use;
  • Complete the Customer Response Form attached to the notice and return by email at [email protected]; and
  • Return all affected lots in possession to Merit Medical Inc. per the instructions found in the Customer Response Form.

Customers are instructed to contact their Merit Sales Representative or Merit Customer Service by telephone at 801.208.4381 with any questions related to this recall.

Healthcare professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by fax to 1-800-FDA-0178.

For more information: www.merit.com; www.fda.gov/Safety/MedWatch/default.htm

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init